Medicilon(SH:688202)2024-07-15 10:28Group 1: Overseas Business Expansion - The company is actively expanding its overseas business and production operations, focusing on multiple core regions globally [2][3] - A new R&D laboratory has been established in Boston, USA, covering chemistry, biology, and animal testing, serving as a strategic point for global deployment [3][4] - The company aims to increase the proportion of overseas business, enhancing communication and collaboration with global partners to meet the growing demands of overseas clients [3][4] Group 2: Operational Improvement Measures - The company plans to optimize its operations by developing new clients, improving the innovative drug R&D platform, and enhancing internal organization and talent structure [4][5] - Efforts will be made to increase project implementation efficiency and ensure orderly operations in response to market changes [4][5] Group 3: Capacity Construction - The company has utilized over 85,000 square meters of R&D office space across various locations, including Shanghai and Boston [4][5] - Ongoing projects include the expansion of the drug discovery and pharmaceutical research laboratory, which has completed its main structure and is awaiting inspection [4][5] Group 4: Industry Outlook - Despite a challenging investment environment, there are new opportunities in drug categories like GLP-1, ADC, and small nucleic acids [5][6] - The Chinese government is focusing on supporting the innovative drug industry through various policy measures, which will provide more opportunities for domestic CRO companies [5][6]